IL174926A0 - Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(-2-chlorophenyl)-methanone - Google Patents

Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(-2-chlorophenyl)-methanone

Info

Publication number
IL174926A0
IL174926A0 IL174926A IL17492606A IL174926A0 IL 174926 A0 IL174926 A0 IL 174926A0 IL 174926 A IL174926 A IL 174926A IL 17492606 A IL17492606 A IL 17492606A IL 174926 A0 IL174926 A0 IL 174926A0
Authority
IL
Israel
Prior art keywords
pyridin
trifluoromethylbenzyl
methanone
triazol
chlorophenyl
Prior art date
Application number
IL174926A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL174926A0 publication Critical patent/IL174926A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
IL174926A 2003-10-24 2006-04-11 Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(-2-chlorophenyl)-methanone IL174926A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (1)

Publication Number Publication Date
IL174926A0 true IL174926A0 (en) 2006-08-20

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174926A IL174926A0 (en) 2003-10-24 2006-04-11 Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(-2-chlorophenyl)-methanone

Country Status (28)

Country Link
US (1) US7381826B2 (cg-RX-API-DMAC10.html)
JP (1) JP4959336B2 (cg-RX-API-DMAC10.html)
KR (1) KR100848407B1 (cg-RX-API-DMAC10.html)
CN (1) CN1863791B (cg-RX-API-DMAC10.html)
AR (1) AR046131A1 (cg-RX-API-DMAC10.html)
AT (1) ATE462700T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004285855B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0415010B8 (cg-RX-API-DMAC10.html)
CA (1) CA2542140C (cg-RX-API-DMAC10.html)
CL (2) CL2009001311A1 (cg-RX-API-DMAC10.html)
CR (1) CR8353A (cg-RX-API-DMAC10.html)
DE (1) DE602004026333D1 (cg-RX-API-DMAC10.html)
DK (1) DK1675846T3 (cg-RX-API-DMAC10.html)
EA (1) EA008881B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066517A (cg-RX-API-DMAC10.html)
ES (1) ES2340772T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100207T1 (cg-RX-API-DMAC10.html)
IL (1) IL174926A0 (cg-RX-API-DMAC10.html)
MA (1) MA28329A1 (cg-RX-API-DMAC10.html)
MY (1) MY157375A (cg-RX-API-DMAC10.html)
NO (1) NO335090B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ545917A (cg-RX-API-DMAC10.html)
PE (1) PE20050481A1 (cg-RX-API-DMAC10.html)
PT (1) PT1675846E (cg-RX-API-DMAC10.html)
TW (1) TW200524906A (cg-RX-API-DMAC10.html)
UA (1) UA82901C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005042515A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200603234B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant
WO2026152024A1 (en) 2025-01-09 2026-07-16 Vanda Pharmaceuticals Inc. Method of treating nausea and vomiting after glp-1r agonist administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
DE60039616D1 (de) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
WO2001032656A1 (en) * 1999-10-29 2001-05-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
NZ580480A (en) 2010-02-26
CA2542140A1 (en) 2005-05-12
KR100848407B1 (ko) 2008-07-28
AR046131A1 (es) 2005-11-23
DE602004026333D1 (de) 2010-05-12
PT1675846E (pt) 2010-04-20
EA008881B1 (ru) 2007-08-31
US20070078166A1 (en) 2007-04-05
CL2009001310A1 (es) 2009-12-04
CN1863791B (zh) 2011-12-07
DK1675846T3 (da) 2010-05-31
NZ545917A (en) 2009-11-27
BRPI0415010B8 (pt) 2021-05-25
AU2004285855A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
EA200600829A1 (ru) 2006-08-25
AU2004285855B8 (en) 2011-04-28
NO335090B1 (no) 2014-09-08
JP4959336B2 (ja) 2012-06-20
CL2009001311A1 (es) 2009-10-02
TW200524906A (en) 2005-08-01
ZA200603234B (en) 2007-07-25
BRPI0415010B1 (pt) 2019-07-09
WO2005042515A1 (en) 2005-05-12
PE20050481A1 (es) 2005-09-20
ATE462700T1 (de) 2010-04-15
US7381826B2 (en) 2008-06-03
HRP20100207T1 (hr) 2010-05-31
CN1863791A (zh) 2006-11-15
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
ECSP066517A (es) 2006-10-10
BRPI0415010A8 (pt) 2018-05-08
CR8353A (es) 2006-06-06
MA28329A1 (fr) 2006-12-01
MY157375A (en) 2016-06-15
UA82901C2 (en) 2008-05-26
KR20060061388A (ko) 2006-06-07
BRPI0415010A (pt) 2006-11-07
AU2004285855B2 (en) 2010-12-23
CA2542140C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
PT1675846E (pt) Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
GB2385167B (en) Improved memory controller
AP2006003534A0 (en) Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
SI2332921T1 (sl) 8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazapin hidroklorid
GB2378707B (en) Liquid crystalline medium
AP2005003383A0 (en) Aminoheteroaryl compounds as protein kinase inhibitors.
IL164608A0 (en) 2-(2,6-Dichlorophenyl)-diarylimidazoles
AU2001263399A1 (en) 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indo linone derivatives
IL175702A0 (en) Nanoscale crystalline silicon-powder
AU2003219410A1 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
ZA200903578B (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
TWI315667B (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl )piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono -hydrochloride
AU2003216677A1 (en) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
IL151566A0 (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
MX252778B (es) Modificacion cristalina ii de la 2-[2 -(1-cloro- ciclopropil)- 3-(2-clorofenil)- 2 hidroxi- propil]-2, 4-dihidro -3h-1, 2, 4-triazol -3-tiona.
EG22745A (en) 2-(3,5-Disbustituted-4-pyridyl)-4-(thienyl) thiazolyl or arylphenyl)1,30xazoline compounds
AU2003260337A1 (en) Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
AU2003250860A1 (en) Chiral 3,4-dihydro-2h-pyran compounds
AU2003228950A8 (en) Oocyte recording chamber
GB2394742B (en) Asymmetric compact for drill bit
AU2002241192A8 (en) Process for the preparation of 1-(2,6,6-trimethyl-2-cyclohexene-1-yl)-but-2-ene-1-one
AU2002334730A1 (en) Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors